Estrogen receptor expression in normal breast epithelium in invasive ductal carcinoma

Abstract

Objectives: Invasive ductal carcinomas (IDCs) are the most important group of malignant breast tumors and constitute 75-80% of breast carcinomas. While IDCs often present with ductal carcinoma in situ (DCIS), they sometimes include a low level of DCIS or they do not include any accompanying DCIS at all. We planned this study to compare estrogen receptor (ER) expression levels in normal mammary epithelium in IDCs with extensive DCIS (Group I) and IDCs without DCIS (Group II).

Methods: Eighty IDC cases selected from among samples that were analyzed in our pathology laboratory. The cases were assessed retrospectively in light of immunohistochemical analysis results and pathology reports. Evaluation of immunohistochemistry: ER positivity in IDC was defined with a nuclear staining of more than 10% of cancer cells regardless of intensity of staining. Presence of cells showing nuclear staining for normal breast epithelium was classified in 4 groups according to their quantity and intensity. These were: 0-None: No staining was observed, 1-Single: One or two positive cells, 2-Dispersed: Dispersed positive cells surrounded by negative cells, 3-Adjoined: 10 or more positive cells contacting each other.

Results: Statistically no significant difference was found between Group I and Group II in terms of ER expression. Group I were more prevalent in younger and in the premenopausal period than Group II.

Conclusions: According to our study, there was no difference between Group I and Group II in terms of ER expression. But the significantly presence Group I in more young people and in premenopausal women suggests that these carcinomas develop due to high estrogen levels and that Group II develop independently than estrogen. This suggests that these groups may have different carcinogenesis and etiologies. We therefore think that this first study on IDCs with extensive DCIS and IDCs without DCIS should be supported by new research studies.

Keywords

• Estrogen reseptor
• breast epithelium
• invasive ductal carcinoma
• ductal carcinoma in situ

References

1. 1. http://www.who.int/news-room/fact-sheets/detail/cancer. Access date: 06.10.2018.
2. 2. Wu T, Li Y, Gong L, Lu JG, Du XL, Zhang WD, et al. Multi-step process of human breast carcinogenesis: a role for BRCA1, BECN1, CCND1, PTEN and UVRAG. Mol Med Rep 2012;5:305-12.
3. 3. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987-91.
4. 4. Oh H, Eliassen AH, Wang M, Smith-Warner SA, Beck AH, Schnitt SJ, et al. Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer 2016;2:16032.
5. 5. Petersen OW, Hoyer PE, van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 1987;47:5748-51.
6. 6. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998;52:261-88.
7. 7. Osborne CK, Yochmowitz MG, Knight WA, 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46(12 Suppl):2884-8.
8. 8. Santen R, Cavalieri E, Rogan E, Russo J, Guttenplan J, Ingle J, et al. Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects. Ann N Y Acad Sci 2009;1155:132-40.

9. 9. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
10. 10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
11. 11. Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 1996;73:5-12.
12. 12. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-47.
13. 13. Rosen PP. The pathological classification of human mammary carcinoma: past, present and future. Ann Clin Lab Sci 1979;9:144-56.
14. 14. Tulinius H, Bjarnason O, Sigvaldason H, Bjarnadottir G, Olafsdottir G. Tumours in Iceland, 10. Malignant tumours of the female breast. A histological classification, laterality, survival and epidemiological considerations. APMIS 1988;96:229-38.
15. 15. Gupta SK, Douglas-Jones AG, Fenn N, Morgan JM, Mansel RE. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer 1997;80:1740-5.
16. 16. Rosen PP. Invasive duct carcinoma: assesment of prognosis, morphologic prognostic markers, and tumor growth rate. Chapter 12. In: Rosen's Breast Pathology. Philadelphia, PA: Lippincott, Williams & Wilkins, 2008: pp.358-404.
17. 17. Hurd TC, Sneige N, Allen PK, Strom EA, McNeese MD, Babiera GV, et al. Impact of extensive intraductal component on recurrence and survival in patients with stage I or II breast cancer treated with breast conservation therapy. Ann Surg Oncol 1997;4:119-24.
18. 18. Rosen PP. Anatomy and physiological morphology. Chapter 1. In: Rosen's Breast Pathology. Philadelphia, PA: Lippincott, Williams & Wilkins, 2008: pp.1-25.
19. 19. Ahmed S, Tartter PI, Brower ST, Weiss SE, Brusco C, Bossolt K, et al. Comparison of invasive cancers with and without extensive intraductal component. Breast Dis 1996;8:1-6.
20. 20. Ricketts D, Turnbull L, Ryal G, Bakhshi R, Rawson NSB, Gazet J-C, et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991;51:1817-22.
21. 21. Drife JO. Breast development in puberty. Ann N Y Acad Sci 1986;464:58-65.
22. 22. Umekita Y, Souda M, Ohi Y, Rai Y, Sagara Y, Yoshida H. Expression of estrogen receptor alpha and progesterone receptor in normal human breast epithelium. In Vivo 2007;21:535-9.
23. 23. Schnitt SJ, Connolly JL, Harris JR, Hellman S, Cohen RB. Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy. Cancer 1984;53:1049-57.
24. 24. Fisher ER, Gregorio R, Redmond C, Vellios F, Sommers SC, Fisher B. Pathologic findings from the national surgical adjuvant breast project. (protocol no. 4): 1. Observations concerning the multicentricity of mammary cancer. Cancer 1975;35:247-54.
25. 25. Xiaohong R. Yang, Jonine D. Figueroa, Stephen M. Hewitt, Roni T. Falk, Ruth M. Pfeiffer, Jolanta Lissowska, Beata Peplonska, Louise A. Brinton, Montserrat Garcia-Closas, and Mark E. Sherman. Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer. Breast Cancer Res Treat 2013;137:837-47.
26. 26. Kumar VL, Srivastava A, Singhal R, Kumar V. Immunoreactive estrogen receptor in breast tumor and adjacent tissue: association with clinicopathological characteristics in Indian population. J Surg Oncol2005;89:251-5.
27. 27. Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol 1990;94:533-7.
28. 28. Woolcott CG, Sen Gupta SK, Hanna WM, Aronson KJ. Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls. BMC Cancer 2008;8:130.
29. 29. Giani C, D’Amore E, Delarue JC, Mouriesse H, May-Levin F, Sancho-Garnier H, et al. Estrogen and progesterone receptors in benign breast tumors and lesions: Relationship with histological and cytological features. Int J Cancer 1986;37:7-10.
30. 30. Rochman H, Conniff ES, Kuk-Nagle KT. Age and incidence of estrogen receptor positive breast tumors. Ann Clin Lab Sci 1985;15:106-8.
31. 31. Ellinidi VN, Anikseeva NV, Goncharova OA, Krasnozhon DA, Fedorov KA. [Immunohistochemical investigation of estrogen and progesterone receptors in breast tumors]. Vopr Onkol 2004;50:234-6. [Article in Russian)
32. 32. Jing X, Kakudo K, Murakami M, Nakamura Y, Nakamura M, Yokoi T, et al. Extensive intraductal component (EIC) and estrogen receptor (ER) status in breast cancer. Pathol Int 1998;48:440-7.